CBSA to honor life science innovators, leaders tonight

CBSA to honor life science innovators, leaders tonight

DENVER -- Colorado BioScience Association (CBSA) will highlight a banner year marked by acquisitions, investments, discoveries and partnerships during its 14 th Annual Awards Dinner tonight in... Read More

Thursday November 9, 2017 0 comments Tags: Denver, CBSA, April Giles, Array BioPharma, miRagen Therapeutics, Sharklet Technologies, Cerescan, Eximis Surgical, Ocugen, Boettcher Foundation

miRagen Therapeutics completes merger with Signal Genetics, raises $40.7M in equity financing

miRagen Therapeutics completes merger with Signal Genetics, raises $40.7M in equity financing

BOULDER -- Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, announced its merger with... Read More

Monday February 20, 2017 0 comments Tags: Boulder, miRagen Therapeutics, Signal Genetics, William S. Marshall

MiRagen Therapeutics, Signal Genetics sign merger agreement

MiRagen Therapeutics, Signal Genetics sign merger agreement

BOULDER --Miragen Therapeutics and California-based Signal Genetics, Inc. (Nasdaq: SGNL) today announced they have entered into a definitive merger agreement in which the stockholders of miRagen... Read More

Tuesday November 1, 2016 0 comments Tags: miRagen Therapeutics, Signal Genetics, William S. Marshall, Samuel D. Riccitelli

CBSA: 2015 was groundbreaking year for life sciences industry

CBSA: 2015 was groundbreaking year for life sciences industry

DENVER -- Colorados life sciences sector had a robust and groundbreaking 2015, according to the Colorado BioScience Association (CBSA), the states advocate for the industry. CBSA reported... Read More

Wednesday December 16, 2015 0 comments Tags: Denver, CBSA, April Giles, Medtronic, Covidien, Nivalis Therapeutics, Precision Biopsy, miRagen Therapeutics, Spectranetics, Surefire Medical, Cerapedics, dbMEDx, Clovis Oncology

miRagen Therapeutics  raises $41M in Series C fundraising round

miRagen Therapeutics raises $41M in Series C fundraising round

BOULDER -- miRagen Therapeutics , a biopharmaceutical company developing innovative microRNA-based therapeutics, announced a Series C preferred stock financing with gross proceeds of $41 million,... Read More

Wednesday November 11, 2015 0 comments Tags: Boulder, miRagen Therapeutics, William Marshall

miRagen Therapeutics and Santaris Pharma expand global alliance for microRNA drug discovery

miRagen Therapeutics and Santaris Pharma expand global alliance for microRNA drug discovery

BOULDER - miRagen Therapeutics and Denmark-based Santaris Pharma A/S announced they are expanding an existing partnership to discover and produce drugs to treat more diseases caused by... Read More

By: Steve Thursday January 10, 2013 0 comments Tags: Boulder, Henrik Oerum, microRNA, miRagen Therapeutics, Santaris Pharma, William Marshall

miRagen Therapeutics named to FierceBiotech's Fierce 15 List of most promising biotech firms

miRagen Therapeutics named to FierceBiotech's Fierce 15 List of most promising biotech firms

BOULDER - FierceBiotech has named miRagen Therapeutics one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. "Over the past... Read More

By: Steve Thursday September 20, 2012 0 comments Tags: biotechnology, Boulder, Fierce 15, FierceBiotech, microRNA, miRagen Therapeutics, Ryan McBride, Servier, William S. Marshall